imited to, cognitive and language deficits, apraxias, depression, delusions and other neuropsychiatric symptoms and signs, and movement and gait abnormalities) which comprises administering to the subject a therapeutically effective amount of a compound to inhibit the binding of an amyloid beta peptide (preferably, A??1-42)with nAChRs, preferable alpha-7 nAChRs, most preferably, human alpha-7 nACh